{'fraction_non_alphanumeric': 0.023346303501945526, 'fraction_numerical': 0.02821011673151751, 'mean_word_length': 5.198795180722891, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Induction of abortion with sulprostone, a uteroselective prostaglandin E2 derivative: intramuscular route of application.

Sulprostone, a new prostaglandin E2-derivative, with high selectivity for the uterine muscle, was tested in 180 women (62 primigravidae) for induction of abortion in the first trimester of pregnancy by intramuscular administration. Total dosages from 500 to 1,500 mcg in single injections of 500 mcg were tested. The injections were given at intervals of 4 to 8 hours. Adequate cervical dilatation was achieved in nearly 94% of the patients with complete abortion in more than 50%. No sulprostone-related complications such as shock or cramps were registered. Side effects were at a tolerable level with concomitant medication being necessary for about one-third of the patients. Optimal effectiveness and acceptability were recorded, at an injection interval of 6 to 8 h and a total dose of 1,000 mcg sulprostone. The application of sulprostone as abortifacient in first trimester pregnancy is discussed.